Hunan Warrant Chiral Pharmaceutical Co., Ltd. – FDA 483, Nov 14, 2025
An FDA inspection of Hunan Warrant Chiral Pharmaceutical Co., Ltd. in Changsha, China, an API manufacturer, identified significant deficiencies in their manufacturing and quality control systems. Observations included inadequate process validation, failure to establish proper yield ranges, and poorly qualified equipment and water systems. Additionally, the firm exhibited insufficient controls for computerized data and inadequate supplier qualification, indicating a lack of robust scientific justification and control over critical processes.
- Inspection date
- November 14, 2025
- Product type
- drugs
ID · 08ed411b-08d0-451c-9b32-602d3a9cb199
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.